Evaluation of guselkumab (Tremfya®) and treatment with different IL-17 inhibitors in patients with psoriatic arthritis in routine clinical practice; cohort, observational and prospective study.
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: JANSSEN-CILAG INTERNATIONAL NV
- Execution start: 19/11/2021
- End of execution: 30/10/2027
- PI: ENRIQUE RAYA ALVAREZ